Mohammad Asad, Ph.D.

Dr. Asad's Research on Glioblastoma Immunosuppression

Dr. Asad's research focuses on glioblastoma (GBM), the most aggressive type of brain tumor. The aim is to understand the mechanisms in the tumor microenvironment (TME) that contribute to immunosuppression, leading to more effective therapies.

Key areas of investigation include immunosuppressive monocytes and myeloid-derived suppressor cells (MDSCs), which hinder the immune response by reducing the effectiveness of innate and adaptive immune cells. Understanding these cells is crucial for developing targeted treatments.

The research also explores tumor-derived extracellular vesicles (EVs) and other soluble mediators that suppress immune responses, to restore immune function. Various models are used, including human and animal studies, ex vivo and 3D systems, patient-derived tumor samples, and immunocompetent murine glioma models.

Identifying the key factors contributing to the immunosuppressive environment will guide the development of targeted therapies designed to reinstate immune function and enhance treatment efficacy. This work also seeks to uncover potential therapeutic targets to disrupt these immunosuppressive mechanisms, ultimately improving patient outcomes. Furthermore, the research aims to provide valuable insights into the complex interactions between tumor cells and the immune system, contributing to the broader field of brain tumor research.